Arrowhead Pharmaceuticals (ARWR) executive compensation, 2026 proxy

Christopher Anzalone, President and Chief Executive Officer, was paid $9M in fiscal 2025, down 27% from $12.4M the year before. The CEO-to-median-employee pay ratio was 55:1, on median employee pay of $163,062.

Filed
January 27, 2026
Annual meeting
March 19, 2026
Pay year
fiscal 2025
Named executives
6
CEO total pay
$9M-27% vs prior year
CEO to median employee
55:1median $163,062
CEO pay in equity
75%$6.8M in awards
Prior say-on-pay support
91%of votes cast
CEO Target Bonus
125%Percentage of target opportunity awarded.
Revenue
$829.4MFiscal 2025 generated revenue.
Cash Balance
$919.4MCash, equivalents, and securities at year-end.

How Anzalone was paid

$9M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary11%Stock awards75%Non-equity incentive14%All other compensation0%

Named executive officers

ExecutiveTotal
Christopher AnzalonePresident and Chief Executive Officer$9,029,861
Daniel ApelChief Financial Officer$1,754,912
Patrick O’BrienChief Operating Officer$3,030,195
James HamiltonChief Medical Officer$2,966,213
Kenneth MyszkowskiFormer Chief Financial Officer$2,660,161
Tracie OliverFormer Chief Commercial Officer$43,193

What changed and why

  • $9MCEO total compensation was $9,029,861 in fiscal 2025 compared to $12,424,418 in fiscal 2024.
  • 91%Stockholders expressed strong support with 91% voting in favor of the say-on-pay proposal.
  • $200KDaniel Apel joined as Chief Financial Officer in April 2025 with a $200,000 relocation bonus.
  • 125%Annual cash incentive bonuses were certified and approved at up to 125% of target levels.
  • $829.4MCompany generated revenue of $829.4 million and recorded a net loss of $1.6 million.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.